The topoisomerase II alpha gene status in primary breast cancer is a predictive marker of the response to anthracycline-based neoadjuvant chemotherapy

详细信息    查看全文

• 作者：Kae Kawachi ; Takeshi Sasaki ; Ayumi Murakami ; Takashi Ishikawa ; Ayako Kito ; Ikuko Ota ; Daisuke Shimizu ; Akinori Nozawa ; Yoji Nagashima ; Rikuo Machinami ; Ichiro Aoki
• 关键词：Anthracycline-based neoadjuvant chemotherapy ; Breast cancer ; Fluorescent in situ hybridization (FISH) ; Immunohistochemistry ; Topoisomerase II alpha (TOP2A)
• 刊名：Pathology - Research and Practice
• 出版年：2010
• 出版时间：15 March 2010
• 年：2010
• 卷：206
• 期：3
• 页码：156-162
• 全文大小：499 K

文摘

This study aimed at evaluating the usefulness of topoisomerase II alpha (TOP2A) for predicting the effect of anthracycline-based neoadjuvant chemotherapy in breast cancer. The TOP2A status was examined using fluorescent in situ hybridization (FISH) in 14 pre-chemotherapeutic breast cancer tissues, and was also assessed by immunohistochemistry (IHC) in 14 pairs of pre- and post-chemotherapeutic breast cancer specimens. TOP2A gene aberration by IHC tended to show a correlation with pathological responses but this was not statistically significant (p=0.060). On the other hand, the low TOP2A/CEP17 ratio correlated with good pathological responses (p=0.012). TOP2A overexpression was not significantly associated with response (p=0.580). Our results thus suggest that the TOP2A/CEP17 ratio may be a useful predictor of the effects of anthracycline-based neoadjuvant chemotherapy in breast cancer.